CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction Association of Cardiovascular Disease With Respiratory Disease Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association
|<<... 13 14 15 16 17 18 19 ...>>|

Original Research2021 Jul 7.

JOURNAL：Eur J Heart Fail. Article Link

Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction

K-P Kresoja, K-P Rommel, R Wachter et al. Keywords: HFpEF; HFpEF; biomarker; fibrosis; inflammation; obesity; proteomics

ABSTRACT

AIMS -  Recent evidence points towards a distinct obese phenotype among patients with heart failure with preserved ejection fraction (HFpEF). We aimed to identify differentially expressed circulating biomarkers in obese HFpEF patients and link them to disease severity and outcomes.

 

METHODS AND RESULTS -  From the LIFE-Heart study, 999 patients with HFpEF and 999 patients without heart failure (no-HF) were selected and 92 circulating serum biomarkers were measured using a proximity extension assay. Elevation of identified biomarkers was validated in 220 patients from the Aldo-DHF trial with diagnosed HFpEF. HFpEF patients were older and had more comorbidities including coronary artery disease and type 2 diabetes as compared to no-HF patients (p<0.05 for all). After adjusting for covariates, Adrenomedullin (ADM), Galectin-9 (Gal-9), Thrombospondin-2 (THBS-2), CD4, and TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) were significantly higher in obese HFpEF (BMI≥30 kg/m2 , n=464) patients as compared to lean HFpEF (BMI<30 kg/m2 , n=535) and obese no-HF patients (BMI≥30 kg/m2 , n=387) (p<0.001 for both), those findings were verified in the Aldo-DHF validation cohort (p<0.001). Except for CD4 these proteins were associated with increased estimates of left atrial pressure in a linear fashion. Importantly, ADM, TRAIL-R2 and CD4 were associated with increased mortality in obese HFpEF patients after adjusting for covariates.

 

CONCLUSION -  Obese HFpEF patients exhibit higher circulating biomarkers of volume expansion (ADM), myocardial fibrosis (THBS-2) and systemic inflammation (Gal-9, CD4) compared to obese non-HFpEF or lean HFpEF. These findings support the clinical definition of a distinct obese HFpEF phenotype and might merit further investigation. This article is protected by copyright. All rights reserved.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top